Extrapolated Biosimilar Indications Won't Get More US Post-Marketing Requirements
This article was originally published in PharmAsia News
Executive Summary
Biosimilars will have the same pharmacovigilance expectations as innovator biologics in the US despite the lack of clinical data for some extrapolated indications.
You may also be interested in...
Biosimilar Interchangeability Requirements Pushed At Inflectra Review
Celltrion is not seeking interchangeable status, but it had data on a single transition from EU-approved Remicade; however, FDA's advisors said data on multiple switches between products would more accurately reflect real-world clinical practice.
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?
One-Page Patient Medication Information Document Moves Forward Under Proposed Rule
After decades of work, the US FDA released proposed requirements for a simplified version of the Medication Guide for all products. Electronic distribution in lieu of paper ‘upon a patient’s request’ would be allowed. Comments sought on the value of consumer testing of the documents.